Trial site
Adana
Adana, Adana 01140, TürkiyeNot linked to an institution yet
- 11running trials
- 6closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 23 trials
- Phase 42 trials
- Phase 1/21 trial
- Status
- Active, not recruiting8 trials
- Completed5 trials
- Recruiting3 trials
- Terminated1 trial
- Lead sponsor
- Novartis Pharmaceuticals17 trials
Running trials
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
NCT05622708· Phase 4· Novartis Pharmaceuticals· Source
Recruiting
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
NCT05682378· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
NCT04940052· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822· Phase 4· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
NCT03591510· Phase 2· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error